HK Stock Market Move | CARSGEN-B (02171) rose by more than 12%. Annual revenue increased more than twice year-on-year. It officially entered the Hong Kong Stock Exchange list yesterday.

CARSGEN-B (02171) surged over 12%, as of press time, it rose 10.78% to 15.42 Hong Kong dollars, with a turnover of 127 million Hong Kong dollars. On the news front, on March 6, Koji Pharmaceuticals released its annual results, with a profit of 126 million yuan, a year-on-year increase of 218.7%; the attributable loss of the parent company narrowed by 87.7% to 97.861 million yuan. The group's revenue mainly comes from Saikai Ze (autologous BCMA CAR-T cell products), with Saikai Ze's main revenue calculated based on the factory price rather than the end-market price. It is worth noting that on March 9, Koji Pharmaceuticals was officially included in the list of Hong Kong Stock Connect. This inclusion reflects the market's recognition of the company's core CAR-T business development potential, operational norms, and stock liquidity, in line with the company's long-term development strategy and the fundamental interests of all shareholders. This move is expected to provide mainland investors with a more convenient investment channel, significantly increase market attention and liquidity, and inject strong momentum into the company's capital market development.